Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
1–1
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella
You may not be if
Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study
Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity
Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study
History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX® or M-M-R II®
Has any blood dyscrasias, leukemia, lymphoma, or other malignant neoplasm affecting the bone marrow or lymphatic systems
Received salicylates within 14 days prior to study vaccination
Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination
Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination
History of seizure disorder, including febrile seizure
Fever illness (\>=102.2 °F \[39.0 °C\] within 72 hours prior to study vaccination
History of thrombocytopenia
Born to a human immunodeficiency virus (HIV)-infected mother
Has a diagnosis of active untreated tuberculosis
Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.
Clareo Health | Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
